Daesang Wellife Signs Business Agreement with Japan's Nutri for Development of Patient Foods

Collaboration Across the Patient Food Market Including Product Research, Development, and Distribution

Daesang Wellife announced on the 22nd that it has signed a business agreement for research and development with Nutri, a Japanese company specializing in patient food products.

Seohun Kyo, CEO of Daesang Wellife (right), and Takemasa Eiji, CEO of Nutri, are posing for a commemorative photo after signing a business agreement.
[Photo by Daesang Wellife]

Through a strategic partnership, the two companies will share various product information and expertise in the patient food market and engage in product research and development.

Daesang Wellife plans to closely cooperate with Nutri, led by the No.1 domestic patient food brand "Newcare." Newcare offers products for a variety of patients, including general patients as well as those with ▲cancer ▲diabetes ▲kidney disease ▲pressure ulcers and burns, and has continued its partnership with Nutri by officially selling Nutri's texture-modified food REF-P1, which helps with the intake of liquid diets.

Nutri is a company with specialized expertise, achieving over 40% market share in Japan's semi-solid food market. The patient food market in Japan is active in various categories such as ▲semi-solid foods ▲texture-modified foods ▲viscosity-variable foods. Based on its accumulated know-how in senior and patient foods in the market, Nutri will collaborate with Daesang Wellife.

A representative from Daesang Wellife stated, "Both companies are leading the food sector for seniors and patients who have difficulty eating in Korea and Japan," and added, "We aim to promote development within the patient food markets of Korea and Japan, where aging issues are intensifying, through the know-how and networks of both companies."

This content was produced with the assistance of AI translation services.